Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1966 1
1968 1
1971 1
1972 2
1974 1
1975 1
1976 6
1977 8
1978 6
1979 5
1980 4
1981 8
1982 9
1983 4
1984 5
1985 11
1986 9
1987 12
1988 14
1989 19
1990 21
1991 14
1992 16
1993 16
1994 13
1995 13
1996 7
1997 11
1998 4
1999 11
2000 10
2001 9
2002 15
2003 11
2004 13
2005 20
2006 11
2007 7
2008 13
2009 10
2010 10
2011 11
2012 14
2013 18
2014 13
2015 16
2016 7
2017 11
2018 8
2019 3
2020 4
2021 6
2022 6
2023 2

Text availability

Article attribute

Article type

Publication date

Search Results

477 results

Results by year

Filters applied: . Clear all
Page 1
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, Shimamura T, Sho M, Kitano M, Cheng AL, Mizumoto K, Chen JS, Furuse J, Funakoshi A, Hatori T, Yamaguchi T, Egawa S, Sato A, Ohashi Y, Okusaka T, Tanaka M. Ueno H, et al. Among authors: ohkawa s. J Clin Oncol. 2013 May 1;31(13):1640-8. doi: 10.1200/JCO.2012.43.3680. Epub 2013 Apr 1. J Clin Oncol. 2013. PMID: 23547081 Clinical Trial.
Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan.
Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, Nagino M, Kondo S, Nagaoka S, Funai J, Koshiji M, Nambu Y, Furuse J, Miyazaki M, Nimura Y. Okusaka T, et al. Among authors: ohkawa s. Br J Cancer. 2010 Aug 10;103(4):469-74. doi: 10.1038/sj.bjc.6605779. Epub 2010 Jul 13. Br J Cancer. 2010. PMID: 20628385 Free PMC article. Clinical Trial.
[PPoma].
Ohkawa S. Ohkawa S. Nihon Rinsho. 2006 Sep 28;Suppl 3:355-7. Nihon Rinsho. 2006. PMID: 17022563 Review. Japanese. No abstract available.
CT in hanging.
Ohkawa S, Yamadori A. Ohkawa S, et al. Neuroradiology. 1993;35(8):591. doi: 10.1007/BF00588401. Neuroradiology. 1993. PMID: 8278038 No abstract available.
[Pulmonary arteritis].
Ito Y, Ohkawa S. Ito Y, et al. Among authors: ohkawa s. Ryoikibetsu Shokogun Shirizu. 1996;(15):606-10. Ryoikibetsu Shokogun Shirizu. 1996. PMID: 9048107 Review. Japanese. No abstract available.
S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial.
Kudo M, Moriguchi M, Numata K, Hidaka H, Tanaka H, Ikeda M, Kawazoe S, Ohkawa S, Sato Y, Kaneko S, Furuse J, Takeuchi M, Fang X, Date Y, Takeuchi M, Okusaka T. Kudo M, et al. Among authors: ohkawa s. Lancet Gastroenterol Hepatol. 2017 Jun;2(6):407-417. doi: 10.1016/S2468-1253(17)30072-9. Epub 2017 Apr 6. Lancet Gastroenterol Hepatol. 2017. PMID: 28497756 Clinical Trial.
Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer.
Ioka T, Komatsu Y, Mizuno N, Tsuji A, Ohkawa S, Tanaka M, Iguchi H, Ishiguro A, Kitano M, Satoh T, Yamaguchi T, Takeda K, Kida M, Eguchi K, Ito T, Munakata M, Itoi T, Furuse J, Hamada C, Sakata Y. Ioka T, et al. Among authors: ohkawa s. Br J Cancer. 2017 Feb 14;116(4):464-471. doi: 10.1038/bjc.2016.436. Epub 2017 Jan 12. Br J Cancer. 2017. PMID: 28081543 Free PMC article. Clinical Trial.
477 results